What can be used to impetigo treatment market By drug class
“Impetigo Treatment Market – Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global Impetigo treatment market was valued at US$ 448.6 Mn in 2017 and expected to reach US$ 856.2 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026.
The global impetigo treatment market identified to be worth US$ 856.2 Mn by 2026 from US$ 448.6 Mn in 2017, growing at a CAGR of 7.3% during the forecast period from 2018 to 2026. The impetigo is a superficial skin infection caused by gram-positive bacteria, Staphylococcus aureus or Streptococcus pyogenes. The infection is reported to be highly prevalent in children under the age of 14. According to Asha C. Bowen, et al. “The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma”. PLoS One 2015; 10(8), the global point-prevalence of impetigo has risen from 111 million in 2000 to 162 million in 2015, and the majority of the cases are observed in Oceania region particularly in low & middle-income countries. High point-prevalence of impetigo is the prime factor accounting to the surge of the impetigo treatment market. Additionally, the awareness regarding pediatric skin diseases and growing healthcare infrastructure fuel the market growth. Moreover, the evolving resistance of the microbes due to frequent usage is a prime concern and burdens the manufacturers to develop effective antibiotics, thereby accounting for market growth.
Based on the drug class, the global impetigo treatment market is segmented into cephalosporins, fusidane, lincosamide, penicillin, penicillin-like antibiotics, pleuromutilin, pseudomonic acid A, quinolone, sulfonamides and folic acid inhibitors, and tetracyclines. In 2017, penicillin segment dominated the global impetigo treatment market due to high preference by the physicians. Penicillin-like antibiotics segment tailed the penicillin segment and accounted for over 15% of the global share, in terms of value.
Based on geographical demarcation, in 2017, North America led the global market with over 34% of the market share, in terms of value, and expected to retain its lead during the forecast period. The well-established healthcare infrastructure and growing awareness regarding skin diseases are the prime factors for the supremacy of North America. Europe tailed North America followed by Asia Pacific region, in terms of value. Since the fusidane/fusidic acid is not available in the United States, so the treatment pattern vary from the European region.
The global impetigo treatment market witness the presence of numerous players as the treatment includes antibiotics only. Several global and local manufacturers compete in the market and form a fragmented market. Some of the key players in the market include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
What are the types of impetigo? What are impetigo symptoms and signs? What does impetigo look like?
There are two forms of impetigo:
This is the more common form, caused by both staph and strep bacteria. This form initially manifests as small red papules similar to insect bites. These lesions rapidly evolve to small blisters and then to pustules that finally scab over with a characteristic honey-colored crust. This entire process usually takes about one week. These lesions often start around the nose and on the face, but less frequently they may also affect the arms and legs. At times, there may be non-tender but swollen lymph nodes (glands) nearby.
This form of impetigo is caused only by staph bacteria. These bacteria produce a toxin that reduces cell-to-cell stickiness (adhesion), causing separation between the top skin layer (epidermis) and the lower layer (dermis). This leads to the formation of a blister. (The medical term for blister is bulla.) Bullae can appear in various skin areas, especially the buttocks and trunk. These blisters are fragile and contain a clear yellow-colored fluid. The bullae are delicate and often break with the overlying “roof” of skin lost, leaving red, raw skin with a ragged edge. A dark crust will commonly develop during the final stages of development. With healing, this crust will resolve.
View Source – https://www.medicinenet.com/
The global impetigo treatment market expected to reach US$ 856.2 Mn by 2026 from US$ 448.6 Mn in 2017, growing at a CAGR of 7.3% during the forecast period from 2018 to 2026. Impetigo is a skin bacterial infection caused primarily by Staphylococcus aureus or Streptococcus pyogenes.
Penicillin & Penicillin-Like Antibiotics Expected to Drive the Market during the Forecast Period:
In 2017, penicillin and penicillin-like antibiotics together accounted for over 34% of the global impetigo treatment market. The two segments collectively expected to drive the global market. Antibiotics treatment is preferred to reduce the healing duration as most of the impetigo infections are resolved naturally.
North America will Continue to Retain its Dominance during the Forecast Period:
In 2017, North America led the global impetigo treatment market with around 34% of the market share, in terms of value. The United States dominated the North America market due to presence of healthcare infrastructure and high awareness regarding impetigo.
Focus on the Research and Development for Novel Drug Molecules expected to Fuel the Market:
With the growing usage of the antibiotics, the microorganisms are adapting to current antibiotics through genome modifications, which hinders the treatment pattern. Many studies had reported methicillin-resistant S aureus (MRSA) and macrolide-resistant Streptococcus earlier and current studies have reported fusidic acid resistant bacteria.
What Causes Impetigo?
(Source: https://www.fda.gov/) Two types of bacteria found on our skin cause impetigo: Staphylococcus aureus and Streptococcus pyogenes (which also causes strep throat). Most of us go about our lives carrying around these bacteria without a problem, Smith says. But then a minor cut, scrape or insect bite allows the bacteria to cause an infection, resulting in impetigo.
Anyone can get impetigo — and more than once, Smith says. Although impetigo is a year-round disease, it occurs most often during the warm weather months. There are more than 3 million cases of impetigo in the United States every year.
“We typically see impetigo with kids 2 to 6 years old, probably because they get more cuts and scrapes and scratch more. And that spreads the bacteria,” Smith says.